Improved practical value of the FIGO 2023 staging system in evaluating prognosis of early stages endometrial carcinoma
- 2 April 2025
- journal article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 170 (3) , 1170-1178
Abstract
Objective: To investigate the practical value of the International Federation of Gynecology and Obstetrics (FIGO) 2023 endometrial cancer (EC) staging system.Methods: Data on clinicopathological characteristics of patients diagnosed with EC at Tianjin Central Hospital of Gynecology Obstetrics from January 2015 to December 2017 were collected. Initial staging was performed using the FIGO 2009 system, followed by revised staging with the 2023 FIGO system. The oncological outcomes of patients under the different staging systems were analyzed.Results: A total of 671 patients with EC were included in this study, and after applying the 2023 FIGO staging system, the staging of 119 (17.73%) patients changed, with 11 (1.64%) patients experiencing downstaging and 108 (16.10%) patients experiencing upstaging; 5‐year progression‐free survival (PFS) and overall survival (OS) rates changed in stage I (97.75%–98.55% and 98.79%–99.38%, respectively) and stage II (91.39%–93.16% and 95.65%–95.72%, respectively) patients, and the differences in PFS (P = 0.060 and P = 0.001, respectively) and OS (P = 0.349 and P = 0.003, respectively) between stage I and stage II patients became statistically significant. After the restaging of FIGO 2009 stage I patients, there were statistically significant differences in PFS (P = 0.002 and P = 0.024, respectively) and OS (P = 0.002 and P = 0.002, respectively) between stage IIB and IA1 and IA2 patients, and significant differences in PFS (P = 0.022) and OS (P = 0.048) were observed between stage IIC and IA1 patients. In FIGO 2023 stage IIB and IIC patients, the differences in PFS (P = 0.39 and P = 0.39, respectively) and OS (P = 0.78 and P = 0.5, respectively) were not statistically significant among the various FIGO 2009 stages.Conclusion: In the FIGO 2023 EC staging system, stage I and II staging criteria are more reasonable, and the addition of stage IIB and IIC helps to better evaluate patient prognosis.Keywords
This publication has 24 references indexed in Scilit:
- FIGO 2023 staging system predicts not only survival outcome but also recurrence pattern in corpus-confined endometrial cancer patientsTaiwanese Journal of Obstetrics and Gynecology, 2025
- FIGO 2023 staging for endometrial cancer, when, if it is not now?European Journal of Cancer, 2024
- Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancerEuropean Journal of Cancer, 2024
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Incidence of omental metastasis in uterine serous carcinoma: a systematic review and meta-analysisJournal of Gynecology Obstetrics and Human Reproduction, 2022
- Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancerBrachytherapy, 2021
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histologyGynecologic Oncology, 2016
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trialsEuropean Journal of Cancer, 2015
- New surgical staging of endometrial cancer: 20 years laterInternational Journal of Gynecology & Obstetrics, 2009